RhumbLine Advisers
OVID icon

RhumbLine Advisers’s Ovid Therapeutics OVID Stock Holding History

RhumbLine Advisers’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-80,917
Closed -$25.2K – 4229
2025
Q1 		$25.2K Sell
80,917
-3,161
-4% -$1.94K ﹤0.01% 3705
2024
Q4 		$78.5K Buy
84,078
+15,355
+22% +$17.2K ﹤0.01% 3543
2024
Q3 		$81.1K Sell
68,723
-1,010
-1% -$1.05K ﹤0.01% 3571
2024
Q2 		$53.6K Sell
69,733
-12,851
-16% -$35.8K ﹤0.01% 3663
2024
Q1 		$252K Buy
82,584
+2,918
+4% +$9.76K ﹤0.01% 3066
2023
Q4 		$257K Sell
79,666
-3,125
-4% -$10.7K ﹤0.01% 3058
2023
Q3 		$318K Buy
82,791
+4,023
+5% +$14.5K ﹤0.01% 2900
2023
Q2 		$258K Buy
+78,768
New +$267K ﹤0.01% 3099
2021
Q2 		– Sell
-48,990
Closed -$197K – 3077
2021
Q1 		$197K Sell
48,990
-680
-1% -$2.26K ﹤0.01% 2835
2020
Q4 		$115K Buy
49,670
+3,390
+7% +$15.8K ﹤0.01% 2952
2020
Q3 		$266K Sell
46,280
-1,945
-4% -$13K ﹤0.01% 2566
2020
Q2 		$355K Buy
+48,225
New +$226K ﹤0.01% 2491
2019
Q2 		– Sell
-17,010
Closed -$30K – 3000
2019
Q1 		$30K Buy
17,010
+459
+3% +$1.15K ﹤0.01% 2930
2018
Q4 		$40K Buy
16,551
+5,310
+47% +$24.2K ﹤0.01% 2956
2018
Q3 		$64K Sell
11,241
-575
-5% -$4.36K ﹤0.01% 2899
2018
Q2 		$92K Buy
+11,816
New +$101K ﹤0.01% 2879

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

RhumbLine Advisers's OVID Position: Q2 2025 in Review

RhumbLine Advisers sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 80,917 shares — an estimated $25.2K sold.

RhumbLine Advisers first reported a position in OVID in Q2 2018 and held it in 16 quarters. The position peaked at $355K in Q2 2020. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • RhumbLine Advisers reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 80,917 Ovid Therapeutics shares in Q2 2025, an estimated $25.2K.
  • RhumbLine Advisers first reported a position in Ovid Therapeutics in Q2 2018 and held it in 16 quarters.
  • RhumbLine Advisers's Ovid Therapeutics position peaked at $355K in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.